Faculty of Chemistry, University of Warsaw, 1 Pasteura, Warsaw, PL 02-093, Poland.
Biological and Chemical Research Center, University of Warsaw, 101 Żwirki i Wigury Av., Warsaw, PL 02-089, Poland.
ACS Biomater Sci Eng. 2024 Oct 14;10(10):6415-6424. doi: 10.1021/acsbiomaterials.4c01721. Epub 2024 Oct 2.
This study aims to design microgels for controlled drug release via enzymatically generated pH changes in the presence of glucose. Modern medicine is focused on developing smart delivery systems with controlled release capabilities. In response to this demand, we present the synthesis, characterization, and enzymatically triggered drug release behavior of microgels based on poly(acrylic acid) modified with glucose oxidase (GOx) (p(AA-BIS)-GOx). TEM images revealed that the sizes of air-dried p(AA-BIS)-GOx microgels were approximately 130 nm. DLS measurements showed glucose-triggered microgel size changes upon glucose addition, which depended on buffer concentration. Enzymatically triggered drug release experiments using doxorubicin-loaded microgels with immobilized GOx demonstrated that drug release is strongly dependent on glucose and buffer concentration. The highest differences in release triggered by 5 and 25 mM glucose were observed in HEPES buffer at concentrations of 3 and 9 mM. Under these conditions, 80 and 52% of DOX were released with 25 mM glucose, while 47 and 28% of DOX were released with 5 mM glucose. The interstitial glucose concentration in a tumor ranges from ∼15 to 50 mM. Normal fasting blood glucose levels are about 5.5 mM, and postprandial (2 h after a meal) glucose levels should be less than 7.8 mM. The obtained results highlight the microgel's potential for drug delivery using the enhanced permeability and retention (EPR) effect, where drug release is controlled by enzymatically generated pH changes in response to elevated glucose concentrations.
本研究旨在设计通过在葡萄糖存在下酶促产生的 pH 变化来控制药物释放的微凝胶。现代医学专注于开发具有控释能力的智能输送系统。针对这一需求,我们提出了基于葡萄糖氧化酶(GOx)修饰的聚丙烯酸(p(AA-BIS)-GOx)的微凝胶的合成、表征和酶触发药物释放行为。TEM 图像显示,空气干燥的 p(AA-BIS)-GOx 微凝胶的尺寸约为 130nm。DLS 测量表明,葡萄糖的加入导致葡萄糖氧化酶固定化的载药微凝胶的尺寸发生变化,这取决于缓冲液的浓度。使用固定化 GOx 的载有阿霉素的微凝胶进行酶触发药物释放实验表明,药物释放强烈依赖于葡萄糖和缓冲液浓度。在 HEPES 缓冲液中,在浓度为 3 和 9mM 时,观察到 5 和 25mM 葡萄糖触发的释放差异最大。在这些条件下,用 25mM 葡萄糖释放 80%和 52%的 DOX,而用 5mM 葡萄糖释放 47%和 28%的 DOX。肿瘤内的间质葡萄糖浓度范围约为 15 至 50mM。正常空腹血糖水平约为 5.5mM,餐后(餐后 2 小时)血糖水平应低于 7.8mM。所得结果突出了微凝胶在利用增强的通透性和保留(EPR)效应进行药物输送方面的潜力,其中药物释放通过响应升高的葡萄糖浓度的酶促产生的 pH 变化来控制。